652 related articles for article (PubMed ID: 19451504)
1. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
2. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
3. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
[TBL] [Abstract][Full Text] [Related]
6. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
7. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Amano M; Grant A; Kerdel FA
Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
[TBL] [Abstract][Full Text] [Related]
8. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
11. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
15. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
16. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
19. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
Gulliver WP; Jemec GB; Baker KA
J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
[TBL] [Abstract][Full Text] [Related]
20. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
Alecsandru D; Padilla B; Izquierdo JA; Fernández-Cruz E; Sánchez-Ramón S
Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
